Debiopharm Research & Manufacturing SA

1. An innovative, agile business model - Debiopharm acts as a pharma "architect": the company identifies promising molecules worldwide, acquires their license, develops them and collaborates with partners to bring them to market. This model enables innovation and independence without the constraints of a stock market flotation  . - It is committed to areas of high medical need such as oncology and infectious diseases, with a strategy focused on the patient and quality of life  . 2. Recognized expertise in drug development - Debiopharm is the originator of products that have become global standards: triptorelin and oxaliplatin, two drugs on the WHO's list of essential medicines . - Its pipeline also includes innovative therapeutic advances: notably inhibitors such as Debio 0123 (glioblastoma), ADCs (blood cancers), treatments for acromegaly, and next-generation antibiotics  . 3. An inclusive and dynamic corporate culture - Diversity is a key asset: Debiopharm boasts over 40 nationalities, with an inclusive and respectful working environment . - Gender equality initiatives are effective: 50% of management positions are held by women, with a certified fair pay policy . 4. A strong commitment to team well-being - The company values quality of life at work: healthy catering, social activities (yoga, sports, events), psychological support and rewards for in-house innovations ("Shapers Award" program) are in place . - It also offers tangible benefits: maternity leave longer than the legal norm, higher pension contributions, insurance and diversified services . 5. A modern, strategic location - Present in Lausanne (headquarters) and Martigny (R&D and production), Debiopharm benefits from a strong local anchoring: 31% of its employees live in Martigny, and 81% reside in the canton of Valais . - The Martigny site is certified (Swissmedic, FDA, KFDA) and employs around 150 staff for research and production  .

Debiopharm is already very successful, but I think that better communication about its innovations, especially to the general public, could further enhance its image. And with the rapid evolution of technologies, continuing to invest in AI and digital tools would be an added bonus."